A phase III randomized study of BBI608 and best supportive care versus placebo and best supportive care in patients with pretreated advanced colorectal carcinoma.
The primary objective of CO.23 is to compare Overall Survival (OS), defined as the time from randomization until death from any cause, in patients with pre-treated advanced colorectal carcinoma treated with BBI608 plus best supportive care versus placebo plus best supportive care.
Boston Biomedical Inc
Adults 18 and over. Histologically confirmed advanced colorectal cancer that is unresectable.